Help - Search - Members - Calendar
Full Version: How Humans Make Up For An 'Inborn' Vitamin C Deficiency
Mind and Muscle Forums > Chemically Correct > Neuroscience, Health & Longevity
SteveSliwa
How Humans Make Up For An 'Inborn' Vitamin C Deficiency
ScienceDaily (Mar. 21, 2008) — A new study appears to explain how humans, along with other higher primates, guinea pigs and fruit bats, get by with what some have called an "inborn metabolic error": an inability to produce vitamin C from glucose.

Unlike the more than 4,000 other species of mammals who manufacture vitamin C, and lots of it, the red blood cells of the handful of vitamin C-defective species are specially equipped to suck up the vitamin's oxidized form, so-called L-dehydroascorbic acid (DHA), the researchers report in the March21st issue of Cell, a publication of Cell Press. Once inside the blood cells, that DHA--which is immediately transformed back into ascorbic acid (a.k.a. vitamin C)--can be efficiently carried through the bloodstream to the rest of the body, the researchers suggest.

"Evolution is amazing. Even though people talk about this as an 'inborn error'--a metabolic defect that all humans have--there is also this incredible manner in which we've responded to the defect, using some of the body's most plentiful cells," said Naomi Taylor of Université Montpellier I and II in France, noting that the body harbors billions of red blood cells. "[Through evolution], we've created this system that takes out the oxidized form of vitamin C and transports the essential, antioxidant form."

Meanwhile, the red cells of other mammals apparently take up very little, if any, DHA, which might explain why they need to produce so much more vitamin C than we need to get from our diets, Taylor said. The recommended daily dose of vitamin C for humans is just one mg/kg, while goats, for example, produce the vitamin at a striking rate of 200 mg/kg each day.

In essence, the red cells of animals that can't make vitamin C recycle what little they've got. Earlier studies had described the recycling process, Taylor said. "Our contribution to the whole story is to show that this process of recycling exists specifically in mammals that don't make vitamin C."

Scientists knew that the protein called Glut1, found in the membranes of cells throughout the body, is the primary transporter of glucose. They also knew that Glut1 can transport DHA too, thanks to the structural similarities between the two molecules. In biochemical assays, it appeared that the glucose transporter would move glucose and DHA interchangeably.

But, in the new study, Taylor's group made a surprising discovery: The Glut1 on human red blood cells strongly favors DHA over glucose. In fact, the human blood cells are known to carry more Glut1 than any other cell type, harboring more than 200,000 molecules on the surface of every cell. Nevertheless, the researchers found, as red blood cells develop in the bone marrow, their transport of glucose declines even as Glut1 numbers skyrocket.

The key to the glucose transporters switch to DHA, they show, is the presence of another membrane protein called stomatin. (Accordingly, in patients with a rare genetic disorder of red cell membrane permeability wherein stomatin is only present at low levels, DHA transport is decreased by 50% while glucose uptake is significantly increased, they report.)

Then, another surprise: The researchers found that the red cells of mice, a species that can produce vitamin C, don't carry Glut1 on their red blood cells at all. They carry Glut4 instead. They suspected that the differences in human red blood cells might be linked to our inability to synthesize the reduced form of DHA, vitamin C, from glucose. In fact, they confirmed Glut1 expression on human, guinea pig and fruit bat red blood cells, but not on any other mammalian red cells tested, including rabbit, rat, cat, dog and chinchilla. Next, they took a closer look at primates. Primates belonging to the Haplorrhini suborder (including prosimian tarsiers, new world monkeys, old world monkeys, humans and apes) have lost the ability to synthesize vitamin C, whereas primates in the Strepsirrhini suborder (including lemurs) are reportedly able to produce this vitamin, Taylor explained.

Notably, they detected Glut1 on all tested red blood cells of primates within the higher primate group, including long-tailed macaques, rhesus monkeys, baboons and magot monkeys. In marked contrast, Glut1 was not detected on lemur red blood cells. Moreover, they report, although DHA uptake in human and magot red cells was similar, the level of transport in cells from three different lemur species was less than 10% of that detected in higher primates.

"Red blood cell-specific Glut1 expression and DHA transport are specific traits of the few vitamin C-deficient mammalian species, encompassing only higher primates, guinea pigs and fruit bats," the researchers concluded. "Indeed, the red cells of adult mice do not harbor Glut1 and do not transport DHA. Rather, Glut4 is expressed on their cells. Thus, the concomitant induction of Glut1 and stomatin during red blood cell differentiation constitutes a compensatory mechanism in mammals that are unable to synthesize the essential ascorbic acid metabolite," otherwise known as vitamin C.

The researchers include Amelie Montel-Hagen, Institut de Genetique Moleculaire de Montpellier, CNRS, Universite´ Montpellier I and II, Montpellier, France; Sandrina Kinet, Institut de Genetique Moleculaire de Montpellier, CNRS, Universite´ Montpellier I and II, Montpellier, France; Nicolas Manel, Institut de Genetique Moleculaire de Montpellier, CNRS, Universite´ Montpellier I and II, Montpellier, France; Cedric Mongellaz, Institut de Genetique Moleculaire de Montpellier, CNRS, Universite´ Montpellier I and II, Montpellier, France; Rainer Prohaska, Max F. Perutz Laboratories, Department of Medical Biochemistry, Medical University of Vienna, Vienna, Austria; Jean-Luc Battini, Institut de Genetique Moleculaire de Montpellier, CNRS, Universite´ Montpellier I and II, Montpellier, France; Jean Delaunay, Hematologie, Hopital de Bicetre, APHP, INSERM U779, Faculte´ de Medecine Paris-Sud, Le Kremlin-Bicetre, France; Marc Sitbon, Institut de Genetique Moleculaire de Montpellier, CNRS, Universite´ Montpellier I and II, Montpellier, France; and Naomi Taylor, Institut de Genetique Moleculaire de Montpellier, CNRS, Universite´ Montpellier I and II, Montpellier, France.

Adapted from materials provided by Cell Press, via EurekAlert!, a service of AAAS.

Heavy_Lifter85
Nice find Steve.

-----------------------------------

"Scientists knew that the protein called Glut1, found in the membranes of cells throughout the body, is the primary transporter of glucose. They also knew that Glut1 can transport DHA too, thanks to the structural similarities between the two molecules. In biochemical assays, it appeared that the glucose transporter would move glucose and DHA interchangeably.

But, in the new study, Taylor's group made a surprising discovery: The Glut1 on human red blood cells strongly favors DHA over glucose. In fact, the human blood cells are known to carry more Glut1 than any other cell type, harboring more than 200,000 molecules on the surface of every cell. Nevertheless, the researchers found, as red blood cells develop in the bone marrow, their transport of glucose declines even as Glut1 numbers skyrocket."

Liorrh,

The above was the basis of my earlier assertion that high-CHO intakes might compromise the immune system (by glucose out-competing DHA at the RBC's). Turns out you were right on this about this matter as well.
lynx
Alternative explanation of how we get by without de novo ascorbic acid.

QUOTE
Arch Gerontol Geriatr 1984 Dec;3(4):321-48

Urate and ascorbate: their possible roles as antioxidants in determining longevity of mammalian species.

Cutler RG

Urate has been shown to be a major antioxidant in human serum and was postulated to have a biological role in protecting tissues against the toxic effects of oxygen radicals and in determining the longevity of primates. This possibility has been tested by determining if the maximum lifespan potentials of 22 primate and 17 non-primate mammalian species are positively correlated with the concentration of urate in serum and brain per specific metabolic rate. This analysis is based on the concept that the degree of protection a tissue has against oxygen radicals is proportional to antioxidant concentration per rate of oxygen metabolism of that tissue. Ascorbate, another potentially important antioxidant in determining longevity of mammalian species, was also investigated using this method. The results show a highly significant positive correlation of maximum lifespan potential with the concentration of urate in serum and brain per specific metabolic rate. No significant correlation was found for ascorbate. These results support the hypothesis that urate is biologically active as an antioxidant and is involved in determining the longevity of primate species, particularly for humans and the great apes. Ascorbate appears to have played little or no role as a longevity determinant in mammalian species.
lynx
QUOTE
High levels of urate could slow Parkinson's

High levels of a natural substance in the blood called urate might slow the progression of Parkinson's, a study out today suggests.
The results raise the hope that urate, or a nutritional supplement called inosine that is converted to urate in the body, might slow the disabling symptoms of Parkinson's, a brain disease that affects more than 1 million people in the USA. Right now, drugs for Parkinson's treat the symptoms but do nothing to slow the progression of the devastating disease, says one study author, Alberto Ascherio of the Harvard School of Public Health.

Previous research had noted that healthy people with high blood levels of urate had a reduced risk of developing Parkinson's later in life. To expand on that research, Ascherio, Michael Schwarzschild of the Massachusetts General Hospital and their colleagues studied 800 people with mild Parkinson's. They looked at blood levels of urate naturally present in the blood and the rate of disease progression over a two-year period.

The team did a statistical analysis and discovered that people with the highest levels of urate had about half the risk of getting significantly worse. At the end of the study, these people still did not require treatment with drugs that replace dopamine, a brain chemical that helps regulate movement.

Parkinson's occurs when brain cells that produce dopamine are slowly destroyed. The symptoms of the disease worsen as time goes on and more of these brain cells die, Ascherio says.

The researchers also looked at brain scans and found that people in the top urate group had lost the fewest brain cells that make dopamine.

The findings raise the possibility that urate might help protect brain cells from damage by toxic molecules known as free radicals, says Brian Fiske of the Michael J. Fox Foundation for Parkinson's Research. Urate seems to quell the highly reactive free radicals before they get a chance to injure the crucial brain cells, he says.

The findings, published in the April 14 online edition of the Archives of Neurology, spurred the foundation to fund a Phase 2 trial that will study 90 patients with early Parkinson's. Half will get the supplement inosine, and half will get a placebo. Researchers will try to find out if they can raise urate levels safely.

Extremely high levels of urate can lead to painful kidney stones or a form of arthritis called gout.

If that safety study goes well, researchers could launch a large trial to test inosine's ability to slow the disease's progression, Fiske says. The necessary research could take from five to eight years — a long time for patients who are losing ground to the disease today.

Meanwhile, patients shouldn't rush out to get inosine, which is widely available, because there is no proof that the supplement works.

"Inosine isn't an approved drug for Parkinson's," Fiske says. "That's what we're trying to test."
This is a "lo-fi" version of our main content. To view the full version with more information, formatting and images, please click here.
Invision Power Board © 2001-2008 Invision Power Services, Inc.